Seeking Alpha

Perrigo (PRGO -0.5%) says its partner, Cobrek Pharmaceuticals, has received final FDA approval...

Perrigo (PRGO -0.5%) says its partner, Cobrek Pharmaceuticals, has received final FDA approval for its Abbreviated New Drug Application for betamethasone valerate foam, the generic equivalent of Luxiq Foam. Perrigo has manufactured the product and is preparing to begin shipping on January 15, 2013, in line with the launch date.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs